Evidence map›Paper›PMID 30728679›Full record

ArticleIndian journal of clinical biochemistry : IJCB2019

Antı-β2 Glycoprotein I Antibodies in Children with Rheumatologic Disorders.

Elif Azarsiz, Gamze Eman, Sanem Eren Akarcan, Ezgi Ulusoy Severcan, Neslihan Karaca, Guzide Aksu, Necil Kutukculer

Open access · bronzeAbstract read
In one paragraph

Article in Indian journal of clinical biochemistry : IJCB, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Elif AzarsizDepartment of Pediatric Immunology, Faculty of Medicine, Ege University, 35040 Bornova, Izmir, Turkey.ORCID 0000-0002-2887-7029
Gamze EmanDepartment of Pediatric Immunology, Faculty of Medicine, Ege University, 35040 Bornova, Izmir, Turkey.
Sanem Eren AkarcanDepartment of Pediatric Immunology, Faculty of Medicine, Ege University, 35040 Bornova, Izmir, Turkey.
Ezgi Ulusoy SevercanDepartment of Pediatric Immunology, Faculty of Medicine, Ege University, 35040 Bornova, Izmir, Turkey.
Neslihan KaracaDepartment of Pediatric Immunology, Faculty of Medicine, Ege University, 35040 Bornova, Izmir, Turkey.
Guzide AksuDepartment of Pediatric Immunology, Faculty of Medicine, Ege University, 35040 Bornova, Izmir, Turkey.
Necil KutukculerDepartment of Pediatric Immunology, Faculty of Medicine, Ege University, 35040 Bornova, Izmir, Turkey.
Ege University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anti-beta-2-glycoprotein I antibodies (anti-β2GPI) which are the main antiphospholipid antibodies that characterize the autoimmune "antiphospholipid syndrome" are pathogenic and are contributing to thrombosis. We aimed to evaluate the presence and the diagnostic importance of these antibodies in children with different rheumatologic diseases with or without thrombosis risk. A total of 100 children with different rheumatologic diseases evaluated retrospectively. The mean anti-β2GPI IgG (

Indexed as

Anti-β2GPIAutoimmunityRheumatological disorderThrombosis

Identifiers

PMID30728679
PMCPMC6346611
OpenAlexW2767394783

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.